Abstract. Hypopituitarism is a well-known cause of secondary osteoporosis. However, patients receiving surgery for pituitary tumors or parasellar lesions have not been well studied for their bone sequel in Japan. We measured bone mineral density (BMD) and urinary type I collagen N-telopeptide (uNTX) in 35 postoperative patients including 25 with pituitary tumor (PT), 6 with craniopharyngioma (CP), and 4 others who had not been on sex hormone replacement, raloxifene, or bisphosphonate therapy. Compared with patients with PT, patients with CP had lower BMD and higher uNTX. Five out of 6 patients with CP had BMD lower than 80% of young adult mean (YAM), whereas 11 out of 22 patients with PT had BMD less than 80% of YAM. Patients with CP had significantly lower serum levels of gonadotropins, and they also tended to have lower serum levels of sex steroids, although statistically not significantly. Two postoperative patients with CP on sex steroid replacement, who were not included in the current analysis, had normal BMD. Of all the subjects, the prominent difference between patients with normal BMD and normal value of uNTX and patients with low BMD and elevated uNTX value was that the latter received higher dose of hydrocortisone replacement. The present study confirms postsurgical patients with pituitary or parasellar lesions, especially those with CP, are at high risk for osteopenia. In designing replacement therapy for those patients, it is important to consider bone by minimizing the dose of glucocorticoid, including sex steroids, and using other drugs that protect bone.
HYPOPITUITARISM is frequently encountered in patients after surgery for pituitary tumor (PT) and parasellar tumor including craniopharyngioma (CP). It is well known that osteoporosis and osteopenia are associated with hypopituitarism especially when hypogonadotropic hypogonadism is present [1] [2] [3] . However, bone metabolism has not been well studied in these postsurgical patients. Therefore, we measured bone mineral density (BMD) and a bone resorption marker in patients after surgery of PT and CP. We found that postsurgical patients with CP had more marked bone derangement compared with those with PT.
Materials and Methods
We measured the lean body mass, metabolic bone markers and BMD in 27 patients after surgical removal of PT, 1 patient after surgical removal of pituitary abscess, 3 patients after surgical removal of Rathke's cleft cyst, and 8 patients after surgical removal of CP. Of these patients, 2 patients after surgical removal of PT had been treated with estrogen-progesterone and bisphosphonate, respectively, and 2 patients after surgical removal of CP had been treated with testosterone. Excluding these four pre-treated patients, 35 patients Table 1 . Summary of patients in this study Sex: F; female, M; male Disease: C; craniopharyngioma, P-A; pituitary corticotroph adenoma, P-G; pituitary somatotroph adenoma, P-N; clinically non-functioning pituitary adenoma, P-P; pituitary mammotroph adenoma, AB; pituitary abscess, R; Rathke's cleft cyst Preop-BH: preoperative body height; N.A.: not available; BH: body height; n.t.: not tested; BW: body weight; L-BMD: bone mineral density at lumbar spine; R-BMD: bone mineral density at radial bone; LH: luteinizing hormone; FSH: follicle-stimulating hormone; T: testosterone; E2: estradiol; NTX: urinary type 1 collagen N-telopeptide; Treatment: T; testosterone, R; raloxifen were included in this study. The markers examined in this study were 1) age and sex of patients; 2) preoperative and postoperative body heights; 3) BMD at lumbar spine and radial bone (T-score) with QDR2000 (Hologic Inc., Bedford, MA, USA); 4) serum concentration of LH, FSH, and estradiol or testosterone; 5) urinary type 1 collagen N-telopeptide (uNTX); 6) doses of hydrocortisone and L-thyroxine as replacement therapy. All blood and urinary samples were collected between 8 a.m. and 12 p.m. Informed consent to analyze their data was obtained from all patients. The data were statistically analyzed using Student's t-test or Fisher's exact probability test, and p-value below 0.05 was considered to be significant. The summary of the patients studied is listed in Table 1 -a and 1-b.
Results

1) Comparison of T-score of BMD and uNTX of postoperative patients with PT, CP and other pituitary diseases (Table 2, 3)
There were no statistically significant gender differences in uNTX and BMD (Table 2 ). Therefore, gender had little influence on our analyses.
Compared with postoperative patients with PT, postoperative patients with CP had more frequently lowered BMD (Table 3) . Postoperative patients with CP were more often osteoporotic, as defined as BMD below 70% of YAM (Table 3) . However, statistical analysis revealed no significant differences. uNTX was also elevated more frequently in postoperative patients with CP, compared with postoperative patients with PT (Table 3) . However, statistical analysis revealed no significant differences.
2) The patients' age, age at the initial operation, time interval from the first operation, serum levels of LH, FSH, testosterone and estrogen had little influence on uNTX and T-score of BMD (Table 4) When we compared between patients with uNTX above or below 55 nmolBCE/mmolCRE and between patients with BMD above or below 80% of YAM, we found no statistically significant differences in the mean values of patients' age, age at the initial operation, time interval from the first operation, serum levels of LH, FSH, testosterone and estrogen. Thus, age has little influence on the abnormal bone metabolism seen in postoperative patients with PT or CP. These results were not suggestive of the increase of uNTX and the decrease of BMD due to hypogonadotropic hypogonadism in postoperative patients with PT or CP.
3) Comparison of bone metabolic markers between postoperative patients with PT and CP (Table 5) There was no statistically significant difference in the mean values of uNTX and the mean serum levels of estrogen and testosterone, between postoperative patients with PT and CP. However, both the mean BMD and the mean serum levels of LH and FSH of postoper- ative patients with CP were significantly lower than those of postoperative patients with PT. Thus, although there were no statistically significant differences in the mean values of uNTX and serum concentrations of sex hormones, postoperative patients with CP had significantly prominent hypogonadotropinism and significantly lowered BMD. Two postoperative patients with CP who were treated with testosterone had normal values of uNTX (below 55 nmolBCE/mmolCRE) and BMD (above 80% of YAM).
4) Correlation among uNTX or T-score of BMD, and doses of hydrocortisone and L-thyroxine as replacement therapy (Table 6)
The dose of hydrocortisone in patients with BMD below 80% of YAM or uNTX above 55 nmolBCE/ mmolCRE was significantly higher than the dose in patients with BMD above 80% of YAM or uNTX below 55 nmolBCE/mmolCRE, respectively. The dose of L-thyroxine in patients with BMD below 80% of YAM was significantly higher than the dose in patients with BMD above 80% of YAM. There were no significant differences in the mean doses of L-thyroxine between patients with uNTX above and below 55 nmolBCE/mmolCRE.
Discussion
In the present study, we confirmed that osteopenia is frequently present in postoperative Japanese patients with PT or CP, regardless of age and age at the initial operation. Although the relationship between hypopituitarism and osteoporosis has been well known, few studies are available for postsurgical patients with pituitary or parasellar lesions. In those patients, we measured BMD and uNTX, a bone resorption marker, and found that BMD is lower whereas uNTX is higher in patients with CP than those with PT. Postoperative patients with CP appear to be at high risk in losing bone. To our knowledge, there have been no studies comparing the bone phenotype in patients with CP and PT. Muller et al. reported that the mean volumetric bone mineral density of patients with CP was in the lower normal range, although many of them were on sex hormone replacement [4] . They also suggested that lean male patients were at special risk for a lower BMD [4] . The exact causes of severer bone phenotype in CP are not determined but can only be speculated. Although we failed to find significant differences in serum levels of sex hormones, possibly due to the small number of patients, patients with CP had significantly lower serum levels of gonadotropins and appeared to have lower serum levels of sex hormones, compared with patients with PT. This may account for the more marked bone phenotype in CP. Another possibility is that hypothalamic function will be well preserved in patients with PT receiving transsphenoidal surgery, whereas hypothalamic function is frequently impaired in patients with CP receiving transcranial surgery. Many hormones and cytokines are secreted from the hypothalamus. Among them, leptin is known to inhibit bone formation in the rat [5] . It is known that serum leptin level is elevated in postoperative patients with CP [6, 7] . Roth et al. suggested that the loss of function of hypothalamic leptin receptor reduced sympathetic tone that would stimulate leptin synthesis in adipocytes [6] . Although we did not measure leptin in our patients, its measurement would have provided us more profound insights into this subject.
When we compared patients with BMD in osteoporotic/osteopenic range (as defined by BMD less than 80% of YAM) with patients with normal range, the difference we found was the mean replacement dose of hydrocortisone. Interestingly, higher uNTX values were also associated with higher replacement dose of hydrocortisone. In light of recent epidemiological studies showing there are no safe doses for the development of glucocorticoid-induced osteoporosis, it would be very important to keep the dose of hydrocortisone as low as possible even in the replacement therapy [8] [9] [10] . Along with hydrocortisone, many of our patients were on replacement with L-thyroxine, of which overreplacement is also known to be detrimental to bone [11, 12] . We also found difference in the doses of L-thyroxine between patients with normal BMD and patients with BMD in osteoporotic/osteopenic range, although we failed to find significant difference in the doses of L-thyroxine between patients with elevated values of uNTX and those with normal range of uNTX. Because TSH was recently shown to have possible protective effects on bone, independently of thyroid hormone, it would have been advisable to compare TSH values in our patients [13] . Finally, we excluded the patients who were already on sex hormone replacement or treated with bisphosphonates in the current study. As mentioned before, two patients with CP who had been replaced with sex hormones had normal BMD and uNTX values, suggesting the importance of sex hormone replacement along with other hormones. Wang et al. studied BMD and bone turnover markers in 123 patients treated with long-term testosterone gel including 27 patients with secondary hypogonadism due to pituitary tumors or hypothalamic tumors [14] . They found a decrease in uNTX in the first 6 months of treatment and continuous increase in BMD in the spine [14] . Therefore, we should reconsider the strategy for hormone replacement in patients with postoperative hypopituitarism in light of recent knowledge of bone metabolism.
In conclusion, we found more detrimental bone consequences in postoperative patients with CP compared with those with PT. In deciding hormone replacement for postoperative hypopituitarism patients, it is important to consider bone health, minimize the dose of glucocorticoid and include sex hormones. In the latter respect, raloxifene may be an alternative choice especially for women.
